Access to the conferences will be possible by invitation in order to obtain a connection right.
Please ask for your invitation to :
Lucretia Antonia Mota (EGIR Secretary) :
‘Double diabetes’ occurs when features of insulin resistance and type 2 diabetes develop in an individual with known type 1 diabetes. It is often due to excessive weight gain over time and is characterised by an increasing insulin requirement. The cardiovascular benefits of intensive insulin therapy appear to be attenuated for individuals with this phenotype, which includes dyslipidaemia and higher blood pressure.
In this session I will review currently available evidence for several ‘adjunct’ therapies that have been suggested for add-in with usual insulin treatment for obese individuals with type 1 diabetes, including metformin, GLP-1 agonists and SGLT2 inhibitors. The potential of combination adjunct therapy is now under investigation in the JDRF-funded TTT1 trial.
Professor Petrie graduated from Edinburgh University medical school in 1989. His early clinical training was in Glasgow followed by a PhD on insulin sensitivity and endothelial function (1997) and further clinical and postdoctoral training at the University of Glasgow. He was Reader in Diabetic Medicine at the University of Dundee from 2003 where he led the initiation and successful establishment of the Scottish Diabetes Research Network (SDRN). He returned to Glasgow in 2010 to a chair in Diabetic Medicine.
Throughout his career he has been a driving force in a number of productive national and international research networks, notably the European Group for the Study of Insulin Resistance, of which he was President from 2010 to 2015.
He has made significant contributions to national and international guidelines for health professionals. For example, as member of the joint American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) Technology Committee, he was lead author in 2015 of a statement on the risks and benefits of Insulin Pumps. In 2010, he developed the algorithm on glucose-lowering therapies since used nationally in the Scottish Intercollegiate Guidelines Network (SIGN116) guideline on type 2 diabetes.
Professor Petrie was Associate Editor of the journal of the European Association for the Study of Diabetes (EASD) Diabetologia until joining its Advisory Board in 2014. He is currently a Senior Associate Editor of the journal Cardiovascular Endocrinology.
Professor Petrie is a Trustee of the NovoNordisk UK Research Foundation and has served on grant-awarding panels including the US National Institutes of Health (NIH), the US Juvenile Diabetes Research Foundation (JDRF), the National Health and Medical Research Council of Australia (NHMRC), the European Foundation for the Study of Diabetes (EFSD), the UK National Institute for Healthcare Research (NIHR), the Academy of Finland, Diabetes UK, and the Health Research Boards of Ireland.